
Antonios Douros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5269930/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention Among Patients With Hypertension in the United Kingdom. American Journal of Hypertension, 2022, 35, 42-53.	1.0	11
2	Utilization and longâ€ŧerm persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. British Journal of Clinical Pharmacology, 2022, 88, 994-1009.	1.1	2
3	Effectiveness and safety of direct oral anticoagulants with antiplatelet agents in patients with venous thromboembolism: A multiâ€database cohort study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12643.	1.0	3
4	Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies. Clinical Pharmacology and Therapeutics, 2022, 111, 1248-1257.	2.3	8
5	Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. PLoS ONE, 2022, 17, e0266142.	1.1	13
6	5â€Î± reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A populationâ€based cohort study. British Journal of Clinical Pharmacology, 2022, 88, 3771-3781.	1.1	1
7	Response to: <scp>Realâ€World</scp> Data on the Risk of Ventricular Arrhythmias with Sulfonamides. Clinical Pharmacology and Therapeutics, 2022, 112, 203-203.	2.3	0
8	Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study. American Journal of Medicine, 2021, 134, 606-613.e6.	0.6	6
9	Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis. Pharmacology Research and Perspectives, 2021, 9, e00707.	1.1	7
10	Clobal <scp>COVID</scp> â€19 pandemic and reporting behavior ―An analysis of the Food and Drug Administration adverse events reporting system. Pharmacoepidemiology and Drug Safety, 2021, 30, 707-715.	0.9	12
11	Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and metaâ€analysis of observational studies. British Journal of Clinical Pharmacology, 2021, 87, 3649-3658.	1.1	20
12	Infectious Disease Burden and the Risk of Alzheimer's Disease: A Population-Based Study. Journal of Alzheimer's Disease, 2021, 81, 329-338.	1.2	13
13	Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 697-705.	1.5	8
14	Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. Thrombosis Research, 2021, 202, 128-133.	0.8	9
15	Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study. BMC Health Services Research, 2021, 21, 758.	0.9	8
16	The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. Diabetes, Obesity and Metabolism, 2021, 23, 2502-2512.	2.2	0
17	Investigating Potential Drug-Drug Interactions from Greek e-Prescription Data. Current Drug Safety, 2021, 16, .	0.3	2
18	Control of blood pressure in older patients with heart failure and the risk of mortality: a population-based prospective cohort study. Age and Ageing, 2021, 50, 1173-1181.	0.7	3

ANTONIOS DOUROS

#	Article	IF	CITATIONS
19	Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A populationâ€based cohort study. Diabetes, Obesity and Metabolism, 2020, 22, 254-262.	2.2	6
20	Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis. Annals of Internal Medicine, 2020, 173, 417-425.	2.0	97
21	Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. Diabetes Care, 2020, 43, 2444-2452.	4.3	26
22	Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ, The, 2020, 370, m3342.	3.0	70
23	Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis. European Journal of Clinical Pharmacology, 2020, 76, 1045-1047.	0.8	1
24	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and the risk of urosepsis: A multiâ€site, prevalent newâ€user cohort study. Diabetes, Obesity and Metabolism, 2020, 22, 1648-1658.	2.2	13
25	Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study. BMC Geriatrics, 2020, 20, 22.	1.1	19
26	Author response: Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study. Neurology, 2020, 95, 232-232.	1.5	1
27	Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A populationâ€based cohort study. British Journal of Clinical Pharmacology, 2019, 85, 2378-2389.	1.1	31
28	Degree of serotonin reuptake inhibition of antidepressants and ischemic risk. Neurology, 2019, 93, e1010-e1020.	1.5	22
29	Opioids and the Risk of Infection: A Critical Appraisal of the Pharmacologic and Clinical Evidence. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 565-575.	1.5	26
30	Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies. Drug Safety, 2019, 42, 1135-1148.	1.4	23
31	Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 1496-1503.	4.3	43
32	RE: Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication. Journal of the National Cancer Institute, 2019, 111, 1107-1108.	3.0	1
33	Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study. European Heart Journal, 2019, 40, 2021-2028.	1.0	54
34	Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, e150-e152.	4.3	22
35	Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. Journal of Hypertension, 2019, 37, 1950-1958.	0.3	46
36	What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®. Journal of General Internal Medicine, 2019, 34, 502-503.	1.3	19

ANTONIOS DOUROS

#	Article	IF	CITATIONS
37	Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation. American Journal of Medicine, 2019, 132, 191-199.e12.	0.6	28
38	Non–Vitamin K Antagonist OralÂAnticoagulants and RiskÂofÂSeriousÂLiver Injury. Journal of the American College of Cardiology, 2018, 71, 1105-1113.	1.2	36
39	Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ: British Medical Journal, 2018, 360, k872.	2.4	89
40	Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review. CNS Drugs, 2018, 32, 321-334.	2.7	27
41	Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. Epidemiology, 2018, 29, 904-912.	1.2	14
42	Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ: British Medical Journal, 2018, 363, k4880.	2.4	33
43	FO029HYPERTENSION CONTROL AND MORTALITY IN A COHORT OF OLDER ADULTS. Nephrology Dialysis Transplantation, 2018, 33, i30-i31.	0.4	0
44	Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. Diabetes Care, 2018, 41, 2330-2338.	4.3	32
45	Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ: British Medical Journal, 2018, 362, k2693.	2.4	81
46	Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study. Current Vascular Pharmacology, 2018, 16, 197-203.	0.8	7
47	Drug-induced kidney injury: A large case series from the Berlin Case-Control Surveillance Study. Clinical Nephrology, 2018, 89, 18-26.	0.4	14
48	Risks Associated With Using Sulfonylureas As A Treatment For Type 2 Diabetes. , 2018, , .		0
49	Immobilization and high platelet count are associated with thromboembolic complications in heparin-induced thrombocytopenia. Pharmacoepidemiology and Drug Safety, 2017, 26, 1149-1155.	0.9	3
50	Patterns of longâ€term use of nonâ€vitamin K antagonist oral anticoagulants for nonâ€valvular atrial fibrillation: Quebec observational study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1546-1554.	0.9	18
51	Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care, 2017, 40, 1506-1513.	4.3	64
52	Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study. International Journal of Molecular Sciences, 2016, 17, 114.	1.8	33
53	Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 718-721.	0.7	26
54	Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions. British Journal of Clinical Pharmacology, 2016, 82, 839-848.	1.1	17

ANTONIOS DOUROS

#	Article	IF	CITATIONS
55	Safety issues and drug–drug interactions with commonly used quinolones. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 25-39.	1.5	40
56	Drugâ€induced liver injury: results from the hospitalâ€based <scp>B</scp> erlin Case–Control Surveillance Study. British Journal of Clinical Pharmacology, 2015, 79, 988-999.	1.1	62
57	Estimating kidney function and use of oral antidiabetic drugs in elderly. Fundamental and Clinical Pharmacology, 2015, 29, 321-328.	1.0	17
58	Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1849-1859.	1.5	68
59	Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. European Journal of Clinical Pharmacology, 2014, 70, 453-459.	0.8	27
60	Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome. Thrombosis and Haemostasis, 2014, 112, 419-420.	1.8	18
61	Ramipril-Induced Liver Injury: Case Report and Review of the Literature. American Journal of Hypertension, 2013, 26, 1070-1075.	1.0	17
62	Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance	1.9	25

study of 102 cases. Alimentary Pharmacology and Therapeutics, 2013, 38, 825-834.